Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
- Press release covers financial results and recent corporate developments
- Conference call and webcast scheduled to discuss Q2 performance
- Detailed figures and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure furnished as Exhibit 99.1, with substantive information contained in the attached exhibit
- Disclosure not deemed “filed” under Exchange Act Section 18, limiting associated liability exposure
- Exhibit 99.1 not incorporated into other SEC filings unless expressly referenced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.